Oral extended release of dexamethasone: Montmorillonite-PLGA nanocomposites as a delivery vehicle

Applied Clay Science

Volumn 104, Issue , 2015, Pages 182-188

  Jain, Shilpa ^a   Datta, Monika ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Dexamethasone; Montmorillonite nanocomposites; PLGA particles

Indexed keywords

CLAY MINERALS; COPOLYMERS; DRUG DELIVERY; DRUG DOSAGE; HORMONES; NANOCOMPOSITES; PARTICLE SIZE; POLYMER BLENDS; STEROID HORMONES;

ANTI-INFLAMMATORIES; DEXAMETHASONES; DRUG DELIVERY SYSTEM; MONTMORILLONITE NANOCOMPOSITES; MONTMORILLONITES (MT); ORAL ADMINISTRATION; PLGA PARTICLES; POLYMER NANOCOMPOSITE;

DRUG PRODUCTS;

BLOOD; COMPOSITE; DRUG; HYDROPHOBICITY; MONTMORILLONITE; PARTICLE SIZE; PLASMA; POLYMER;

EID: 84920918710     PISSN: 01691317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clay.2014.11.028     Document Type: Article

References (39)

1. Aguzzi P.C., Viseras C., Caramella C. Use of clays as drug delivery systems: possibilities and limitations. Appl. Clay Sci. 2007, 36:22.
2. Ali H., Kalashnikova I., White M.A., Sherman M, Rytting E. Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model. Int. J. Pharm. 2013, 454:149-157.
3. Bergaya F., Detellier C., Lambert J.F., Lagaly G. Introduction to clay polymer nanocomposites (CPN) (Chapter 13). Developments of Clay Science 2013, vol. 5A. Elsevier. Bergaya, Lagaly (Eds.).
4. Chen Q., Zielinski D., Chen J., Koski A., Werst D., Nowak S. A validated, stability-indicating HPLC method for the determination of dexamethasone related substances on dexamethasone-coated drug-eluting stents. J. Pharm. Biomed. Anal. 2008, 48:732-738.
5. Fratoddi I., Venditti I., Cametti C., Palocci C., Chronopoulou L., Marino M., Acconcia F., Russo M.V. Functional polymeric nanoparticles for dexamethasone loading and release. Colloids Surf. B: Biointerfaces 2012, 93:59-66.
6. Gaete G.C., Tsapis N., Besnard M., Bochot A., Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int. J. Pharm. 2007, 331:153-159.
7. Goodwin J.E., Zhang J., Gonzalez D., Albinsson S., Geller D.S. Knockout of the vascular endothelial glucocorticoid receptor abrogates dexamethasone-induced hypertension. J. Hypertens. 2011, 29:1347-1356.
8. Harousseau J.L., Attal M., Leleu X., Troncy J., Pegourie B., Stoppa A.M., Hulin C., Benboubker L., Fuzibet J.G., Renaud M., Moreau P., Avet-Loiseau H. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91(11):1498-1505. (PMID 17043025).
9. Hickey T., Kreutzer D., Burgess D.J., Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 2002, 23:1649-1656.
10. Hurson C.J., Butler J.S., Keating D.T., Murray D.W., Sadlier D.M., O'Byrne J.M. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet. Disord. 2007, 8.
11. Jaber M., Bouchoucha M., Delmotte L., Ethivier C.M., Lambert J.F. Fate of L-DOPA in the presence of inorganic matrices: vectorization or composite material formation?. J. Phys. Chem. C 2011, 115:19216-19225.
12. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2001, 21:2475-2490.
13. Jain S., Datta M. Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride. Appl. Clay Sci. 2014, 99C:42-47.
14. Jain S., Datta M. Naturally occurring clay, montmorillonite, as a drug delivery vehicle for in vitro extended release of venlafaxine hydrochloride. Eur. Chem. Bull. 2014, 3(7):672-681.
15. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 2002, 8:189-212.
16. Kaur M., Datta M. Synthesis and characterization of biodegradable clay-polymer nanocomposites for oral sustained release of anti-inflammatory drug. Eur. Chem. Bull. 2013, 2(9):670-678.
17. Kaur M., Datta M. In vitro release of sodium diclofenac from poloxamer 188 modified montmorillonite as an oral drug delivery vehicle. Int. J. Pharm. Pharm. Sci. 2014, 6(5).
18. Kaur M., Datta M. Diclofenac sodium adsorption onto montmorillonite: adsorption equilibrium studies and drug release kinetics. Adsorpt. Sci. Technol. 2014, 32(5).
19. Kim D.H., Martin C. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 2006, 27:3031-3037.
20. Koichi B., Kohji N. Steroid nanocrystals prepared using the nano-spray dryer B-90. Pharmaceutics 2013, 5:107-114.
21. Lambert J.F., Bergaya F. Smectites-polymer nanocomposites (Chapter 13.1). Handbook of Clay Science 2013, vol. 5A. Developments of Clay Science, Elsevier. Bergaya, Lagaly (Eds.).
22. Laza A.L., Jaber M., Miehé-Brendlé J., Demais H., Le Deit H.L., Delmotte L., Vidal L. Green nanocomposites: synthesis and characterization. J. Nanosci. Nanotechnol. 2007, 7(9):3207-3213.
23. Lee J.S., Chae G.S., Kun T.A., Khang G. Preparation of 5-fluorouracil-loaded poly(l-lactide-co-glycolide) wafer and evaluation of in vitro release behaviour. Macromol. Res. 2003, 1:183-188.
24. Miechel L.T.Z., Gerard H.M.E., Dirk W.G., Jan F.J. In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide). J. Control. Release 2004, 100:347-356.
25. Park P.P., Jonnalagadda S. Predictors of glass transition in the biodegradable polylactide and poly-lactide-co-glycolide polymers. J. Appl. Polym. Sci. 2006, 100:1983-1987.
26. Park J.S., Yang H.N., Jeon S.Y., Woo D.G., Kim M.S., Park K.H. The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis. Biomaterials 2012, 33:8600e8612.
27. Patel H.A., Shah S., Shah D.O., Joshi P.A. Sustained release of venlafaxine from venlafaxine-montmorillonite-polyvinylpyrrolidone composites. Appl. Clay Sci. 2011, 51:126-130.
28. Rhen T., Cidlowski J.A. Anti-inflammatory action of glucocorticoids-new mechanisms for old drugs. New Engl. J. Med. 2005, 353:1711-1723.
29. Schmolka I.R. A review of block polymer surfactants. J. Am. Oil Chem. Soc. 1977, 54:110-116.
30. Seema, Datta M. In vitro sustained delivery of atenolol, an antihypertensive drug using naturally occurring clay mineral montmorillonite as a carrier. Eur. Chem. Bull. 2013, 2(11):942-951.
31. Seema, Datta M. Clay-polymer nanocomposites as a novel drug carrier: synthesis, characterization and controlled release study of propranolol hydrochloride. Appl. Clay Sci. 2013, 80-81:85-92.
32. Seema, Datta M. MMT-PLGA nanocomposites as an oral and controlled release carrier for 5-fluorouracil: a novel approach. Int. J. Pharm. Pharma. Sci. 2013, 5(2):332-341.
33. Seema, Datta M. Organoclay Pluronic F68-montmorillonite, as a sustained release drug delivery vehicle for propranolol hydrochloride. Eur. Chem. Bull. 2014, 3(6):593-604.
34. Till John Paramedic Clinical Training Aid 2011, (Retrieved 30 August).
35. Urbańska J., Karewicz A., Nowakowska M. Polymeric delivery systems for dexamethasone. Life Sci. 2014, 96:1-6.
36. Van de Beek D., de Gans J., McIntyre P., Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. 2007, (1). 10.1002/14651858.CD004405.pub2.
37. Verma R.K., Garg S. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J. Pharm. Biomed. Anal. 2004, 35:449-458.
38. World Health Organization WHO Model List of Essential Medicines 2013.
39. Zhang Z., Grijpma D.W., Feijen J. Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone. J. Control. Release 2006, 111:263-270.